Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05378711 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Results of Physician and Parent Decisions to Treat Selective Mutism With Fluoxetine
A Phase 2 study, sponsored by Michigan State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT05378711: Completed Phase 2 study, sponsored by Michigan State University.
NCT05378711 is a Phase 2 study that has completed, run by Michigan State University. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05378711, a Phase 2 study, has completed, sponsored by Michigan State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The Department of Counseling, Educational Psychology, and Special Education and the Department of Psychiatry at Michigan State University have coordinated efforts to provide a diagnostic and treatment investigation for children, ages seven to eighteen, with Selective Mutism. The purpose of this study is to examine the utility of fluoxetine for the treatment of this debilitating disorder. Fluoxetine is expected to improve social anxiety and selective mutism symptomology.
Interventions
- DRUG Fluoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-01-01 |
| Est. Completion | 2015-05-30 |
| Phase | Phase 2 |
What the finished NCT05378711 record still lists
NCT05378711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Fluoxetine is the first listed.
NCT05378711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05378711 about?
NCT05378711 is a clinical study titled "Evaluating the Results of Physician and Parent Decisions to Treat Selective Mutism With Fluoxetine". The Department of Counseling, Educational Psychology, and Special Education and the Department of Psychiatry at Michigan State University have coordinated efforts to provide a diagnostic and treatment investigation for children, ages seven to eighteen, with Selective Mutism. The purpose of this stud...
What is the current status of trial NCT05378711?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2014-01-01. Estimated completion is 2015-05-30.
What interventions are being tested in trial NCT05378711?
The interventions under investigation include: Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT05378711?
This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05378711's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI